Nifty 50 · Healthcare
Dr. Reddy's Laboratories
Dr. Reddy's is a global pharmaceutical company with strengths in generics, biosimilars, and proprietary products.
DRREDDY · Healthcare
₹1,172.00
+1.00 (+0.09%)
Day High
₹1,172.00
Day Low
₹1,162.10
52W High
₹1,414.90
52W Low
₹1,101.00
Volume today: 10.72 L
PaisaTamil Consensus
HOLDScore 48/100 · Low confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,207
Low ₹1,067 · High ₹1,383
Analyst-style Breakdown
Strong Buy
0
Buy
0
Hold
26
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum30/100
1M -12.6%, 1Y -1.8%
Earnings Trend25/100
Latest quarter revenue ₹8.1k Cr, profit ₹444 Cr
Valuation85/100
P/E 18.0x vs sector median ~35x
Financial Quality78/100
ROE 15.5%, ROCE 14.0%
Technical Position38/100
Trading between 52W low 1101 and high 1415
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹8.1k Cr | ₹444 Cr | ₹5.32 | -5.6% | -68.7% |
| Mar 2026 | ₹7.5k Cr | ₹221 Cr | ₹2.65 | — | — |
| Dec 2025 | ₹8.7k Cr | ₹1.2k Cr | ₹14.53 | — | — |
| Sept 2025 | ₹8.8k Cr | ₹1.4k Cr | ₹0.00 | — | — |
| Jun 2025 | ₹8.5k Cr | ₹1.4k Cr | ₹17.04 | — | — |
Key Ratios
Market Cap
₹1.0 L Cr
P/E Ratio
18.0x
P/B Ratio
3.2x
ROE
15.5%
ROCE
14.0%
Dividend Yield
0.7%
Reference fundamentals for analysis. Verify latest quarterly results before making investment decisions.
Company Overview
Dr. Reddy's sells generics in US, India, Russia, and other markets. It has a growing biosimilar and nutraceutical portfolio.
Strengths
- +Diversified geographic revenue
- +Biosimilar pipeline potential
- +India branded generics growth
- +Strong balance sheet
Risks
- −US generics pricing pressure
- −Russia/CIS geopolitical exposure
- −R&D spend on biosimilars
- −Key product patent cliffs
Investment Analysis
What to watch
- • Dr. Reddy's offers value within large-cap pharma.
- • Biosimilar launches are the growth catalyst.
- • Geographic diversification reduces single-market risk.
| Industry | Pharmaceuticals |
|---|---|
| Sector | Healthcare |
| NSE Symbol | DRREDDY |
| Index Weight | 0.60% |
| Market Cap | ₹1.0 L Cr |
Frequently Asked Questions
Yes. Dr. Reddy's Laboratories is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).